2025 PACC Miami | Isatuximab Subcutaneous by On-Body Injector vs. Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma
Overview
NA
Target Audience
Pharmacists
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE
Date of Release
November 23rd, 2025
-1763851572878.webp&w=3840&q=75)
-1763851492821.webp&w=3840&q=75)